Genelux (NASDAQ:GNLX) Issues Earnings Results

Genelux logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Genelux reported a quarterly loss of $0.23 per share, missing the consensus estimate of a $0.19 loss by $0.04.
  • Shares rose $0.06 to $1.92 in Monday midday trading, but remained below their 50-day and 200-day moving averages and near the 52-week low of $1.77.
  • Analysts’ consensus rating was Moderate Buy, with an average price target of $20.00; company insiders sold 47,903 shares worth about $126,320 over the prior three months.
  • MarketBeat previews the top five stocks to own by December 1st.

Genelux (NASDAQ:GNLX - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.04), Zacks reports.

Genelux Stock Performance

Shares of NASDAQ:GNLX traded up $0.06 during midday trading on Monday, reaching $1.92. 277,007 shares of the company's stock traded hands, compared to its average volume of 256,074. The company has a fifty day simple moving average of $2.31 and a two-hundred day simple moving average of $2.65. Genelux has a 1 year low of $1.77 and a 1 year high of $5.89. The company has a market cap of $86.87 million, a P/E ratio of -2.23 and a beta of 0.68.

Analyst Ratings Changes

Several equities analysts recently weighed in on GNLX shares. Wall Street Zen upgraded shares of Genelux from a "strong sell" rating to a "sell" rating in a report on Tuesday, October 20th. Weiss Ratings reissued a "sell (e+)" rating on shares of Genelux in a research report on Thursday, October 15th. Lucid Cap Mkts upgraded shares of Genelux to a "strong-buy" rating in a research note on Wednesday, September 16th. Finally, Benchmark reaffirmed a "speculative buy" rating on shares of Genelux in a report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $20.00.

Get Our Latest Research Report on GNLX

Insider Buying and Selling at Genelux

In related news, CEO Thomas Zindrick sold 34,463 shares of the business's stock in a transaction on Monday, August 31st. The shares were sold at an average price of $2.67, for a total value of $92,016.21. Following the completion of the sale, the chief executive officer owned 1,226,427 shares of the company's stock, valued at approximately $3,274,560.09. The trade was a 2.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Yong Yu sold 9,683 shares of the company's stock in a transaction on Monday, August 31st. The stock was sold at an average price of $2.75, for a total transaction of $26,628.25. Following the transaction, the insider owned 258,688 shares of the company's stock, valued at $711,392. This represents a 3.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 47,903 shares of company stock valued at $126,320. 7.50% of the stock is owned by insiders.

Genelux Company Profile

(Get Free Report)

Genelux Corporation is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors. The company's lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform.

Read More

Earnings History for Genelux (NASDAQ:GNLX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Genelux Right Now?

Before you consider Genelux, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genelux wasn't on the list.

While Genelux currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines